Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) under the Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding executive share awards rather than a financial performance report.
Material Changes
The filing details a change in the shareholding of Mrs. V. Whyte, a PDMR. On February 28, 2013, she received an award of 11,800 Ordinary Shares under the GlaxoSmithKline 2009 Performance Share Plan. The award was based on a share price of £14.54 per share, reflecting the closing middle market price on February 27, 2013.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or risk factors. It notes that the vesting of the awarded shares is subject to meeting performance criteria over a three-year period. The transaction was advised to the Company and the individual on March 4, 2013.
Investor Verification Checklist
- Verify the vesting conditions and performance criteria for the 2009 Performance Share Plan.
- Confirm the total number of shares held by Mrs. V. Whyte post-award.
- Review the company's broader executive compensation policies in the annual Form 20-F.